Postoperative gemcitabine significantly delayed the development of recurrent disease after complete resection of pancreatic cancer compared with observation alone. These results support the use of gemcitabine as adjuvant chemotherapy in resectable carcinoma of the pancreas. [url=http://jama.ama-assn.org/cgi/content/abstract/297/3/267]Full article on JAMA[/url]